• Kewaunee Scientific posted fiscal 2026 net sales of $282 million, up 17.3%, while net earnings fell to $9.62 million from $11.41 million.
• Diluted EPS slipped to $3.22 from $3.83; EBITDA edged up to $22.43 million from $21.61 million.
• Fourth-quarter net sales dropped 7.5% to $71.4 million; net earnings declined to $3.39 million from $4.85 million.
• Long-term debt decreased to $40.85 million from $60.73 million; debt-to-equity improved to 0.61-to-1 from 0.99-to-1.
• Backlog ended the year at $165.9 million; management cited progress integrating Nu Aire despite tariff-related pressure and volatile project timelines.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kewaunee Scientific Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606231701PR_NEWS_USPR_____CL90360) on June 23, 2026, and is solely responsible for the information contained therein.